Antifibrotic Effect of (−)‐Epicatechin in a Rodent Model of Early Stage HFpEF
Abstract
The prevalence of heart failure with preserved ejection fraction (HFpEF) continues to increase and no effective therapies have been identified. Two‐thirds of HFpEF patients are post‐menopausal women with hypertension and/or metabolic syndrome, key factors of cardiac fibrosis. The goals of this study were: 1) to develop a rat model that displays cardiac features of HFpEF in humans evaluated using a comprehensive panel of physiological endpoints and, 2) to characterize the antifibrotic potential of the cacao flavanol (−)‐epicatechin (Epi) which we have demonstrated to exert such activity in an animal model of muscular dystrophy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2019
- Source ID
- 10.1096/fasebj.2019.33.1_supplement.lb506
Entities
People
- Alejandra Garate Carrillo
- Bruce Ito
- Francisco Villarreal
- Guillermo Ceballos
- Israel Ramirez‐sanchez
- Jeffrey Omens
- Moises Muratt Bustamante Pozo
- Nancy Carson
- Ricardo Garcia
Organizations
- United States Department of Defense
- University of California, San Diego